Cargando…
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/ https://www.ncbi.nlm.nih.gov/pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 |
_version_ | 1783492999847608320 |
---|---|
author | Pop, Lucian Suciu, Ioan Dumitru Ionescu, Olivia Ionescu, Paris Toader, Oana Daniela |
author_facet | Pop, Lucian Suciu, Ioan Dumitru Ionescu, Olivia Ionescu, Paris Toader, Oana Daniela |
author_sort | Pop, Lucian |
collection | PubMed |
description | Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates. |
format | Online Article Text |
id | pubmed-6993292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-69932922020-02-05 The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer Pop, Lucian Suciu, Ioan Dumitru Ionescu, Olivia Ionescu, Paris Toader, Oana Daniela J Med Life Review Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates. Carol Davila University Press 2019 /pmc/articles/PMC6993292/ /pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 Text en ©Carol Davila University Press This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Review Pop, Lucian Suciu, Ioan Dumitru Ionescu, Olivia Ionescu, Paris Toader, Oana Daniela The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title_full | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title_fullStr | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title_full_unstemmed | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title_short | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
title_sort | dual blockade in the neoadjuvant setting of her-2 positive early-stage breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/ https://www.ncbi.nlm.nih.gov/pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 |
work_keys_str_mv | AT poplucian thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT suciuioandumitru thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT ionescuolivia thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT ionescuparis thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT toaderoanadaniela thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT poplucian dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT suciuioandumitru dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT ionescuolivia dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT ionescuparis dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer AT toaderoanadaniela dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer |